<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0015">
 <label>Table 3</label>
 <caption>
  <p>Summary of the Drugs/investigational agents that are currently being explored for the treatment of COVID-19.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center">Compound name</th>
    <th align="center">Category</th>
    <th align="center">Potency against SARS-CoV-2 (
     <italic>in vitro</italic> EC
     <sub>50</sub> or IC
     <sub>50</sub> values in µM)
    </th>
    <th align="center">Mechanism of action</th>
    <th align="center">Major Adverse effects</th>
    <th align="center">Status</th>
    <th align="center">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center">Remdesivir</td>
    <td align="center">Antiviral</td>
    <td align="center">0.77</td>
    <td align="center">RdRp inhibitor</td>
    <td align="center">hypersensitivity- infusion-related and anaphylaxis, elevation in liver transaminases</td>
    <td align="center">Phase 3 clinical trial (NCT04292899), EAU in the USA</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>, 
     <xref rid="b0470" ref-type="bibr">[94]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Lopinavir</td>
    <td align="center">Antiviral</td>
    <td align="center">26.63</td>
    <td align="center">M
     <sup>pro</sup> inhibitor
    </td>
    <td align="center">Serious cardiotoxicity, lactic acidosis, acute renal failure reported in preterm neonates</td>
    <td align="center">Phase 2 clinical trial (NCT04330690)</td>
    <td align="center">
     <xref rid="b0810" ref-type="bibr">[162]</xref>, 
     <xref rid="b0815" ref-type="bibr">[163]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Favipiravir</td>
    <td align="center">Antiviral</td>
    <td align="center">61.8</td>
    <td align="center">RdRp inhibitor</td>
    <td align="center">Teratogenic</td>
    <td align="center">Phase 3 clinical trials (NCT04336904)</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>, 
     <xref rid="b0820" ref-type="bibr">[164]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Ribavirin</td>
    <td align="center">Antiviral</td>
    <td align="center">106.5</td>
    <td align="center">RdRp inhibitor</td>
    <td align="center">Teratogenic, hemolytic anemia</td>
    <td align="center">Phase 3 clinical trials (NCT04392427)</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>, 
     <xref rid="b0825" ref-type="bibr">[165]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Umifenovir</td>
    <td align="center">Antiviral</td>
    <td align="center">4.11</td>
    <td align="center">Fusion inhibitor</td>
    <td align="center">No major adverse effects have been reported.</td>
    <td align="center">Phase 4 clinical trials (NCT04252885)</td>
    <td align="center">
     <xref rid="b0830" ref-type="bibr">[166]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Oseltamivir</td>
    <td align="center">Antiviral</td>
    <td align="center">–</td>
    <td align="center">–</td>
    <td align="center">Steven-Johnson syndrome, anaphylactic reactions, cardiac arrhythmia, seizures have been reported</td>
    <td align="center">Phase 3 clinical trials (NCT04338698)</td>
    <td align="center">
     <xref rid="b0835" ref-type="bibr">[167]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Darunavir</td>
    <td align="center">Antiviral</td>
    <td align="center">–</td>
    <td align="center">M
     <sup>pro</sup> inhibitor
    </td>
    <td align="center">Liver injury, severe skin reactions like erythema multiforme and Steven-Johnson syndrome</td>
    <td align="center">Phase 3 clinical trial (NCT04252274)</td>
    <td align="center">
     <xref rid="b0840" ref-type="bibr">[168]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Teicoplanin</td>
    <td align="center">Antibiotic</td>
    <td align="center">1.66</td>
    <td align="center">Cathepsin L inhibitor</td>
    <td align="center">Not much information is available on the adverse effects associated with teicoplanin</td>
    <td align="center">–</td>
    <td align="center">
     <xref rid="b0235" ref-type="bibr">[47]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Azithromycin</td>
    <td align="center">Antibiotic</td>
    <td align="center">–</td>
    <td align="center">–</td>
    <td align="center">QT interval prolongation, severe hypersensitivity reactions have been reported</td>
    <td align="center">Phase 3 clinical trial (NCT04332107)</td>
    <td align="center">
     <xref rid="b0845" ref-type="bibr">[169]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Carrimycin</td>
    <td align="center">Antibiotic</td>
    <td align="center">–</td>
    <td align="center">–</td>
    <td align="center">Not much clinical data is available on Carrimycin</td>
    <td align="center">Phase 4 clinical trial (NCT04286503)</td>
    <td align="center"/>
   </tr>
   <tr>
    <td align="center">Chloroquine</td>
    <td align="center">Antiprotozoal</td>
    <td align="center">1.13</td>
    <td align="center">Raises the pH in the endocytic vesicles, interferes with terminal glycosylation of ACE-2</td>
    <td align="center">Prolongation of QT interval, hypoglycemia, neuropsychiatric effects</td>
    <td align="center">Phase 3 clinical trial (NCT04303507)</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>, 
     <xref rid="b0850" ref-type="bibr">[170]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Hydroxychloroquine</td>
    <td align="center">Antiprotozoal</td>
    <td align="center">0.72</td>
    <td align="center">Raises the pH in the endocytic vesicles, interferes with terminal glycosylation of ACE-2</td>
    <td align="center">Prolongation of QT interval, hypoglycemia, neuropsychiatric effects</td>
    <td align="center">Phase 3 clinical trial (NCT04340544)</td>
    <td align="center">
     <xref rid="b0635" ref-type="bibr">[127]</xref>, 
     <xref rid="b0850" ref-type="bibr">[170]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Nitazoxanide</td>
    <td align="center">Antiprotozoal</td>
    <td align="center">2.12</td>
    <td align="center">–</td>
    <td align="center">No major adverse effects have been reported</td>
    <td align="center">Phase 2 clinical trial (NCT04423861)</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Ivermectin</td>
    <td align="center">Antiprotozoal</td>
    <td align="center">~2</td>
    <td align="center">–</td>
    <td align="center">No major adverse effects reported</td>
    <td align="center">Phase 2 clinical trial (NCT04438850)</td>
    <td align="center">
     <xref rid="b0695" ref-type="bibr">[139]</xref>
    </td>
   </tr>
   <tr>
    <td align="center">Camostat</td>
    <td align="center">Antifibrinolytic</td>
    <td align="center">–</td>
    <td align="center">TMPRSS2 inhibitor</td>
    <td align="center">Not much information is available on the adverse events</td>
    <td align="center">Phase 2 clinical trial (NCT04374019)</td>
    <td align="center"/>
   </tr>
   <tr>
    <td align="center">Nafamostat</td>
    <td align="center">Anticoagulant</td>
    <td align="center">22.5</td>
    <td align="center">TMPRSS2 inhibitor</td>
    <td align="center">Hyperkalemia, agranulocytosis, anaphylaxis</td>
    <td align="center">Phase 2 clinical trial (NCT04418128)</td>
    <td align="center">
     <xref rid="b0310" ref-type="bibr">[62]</xref>, 
     <xref rid="b0855" ref-type="bibr">[171]</xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
